Omalizumab is indicated for the treatment of persistent asthma, chronic rhinosinusitis with nasal polyps, food allergies and ...

The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.

Tanvex Biopharma announced its biosimilar drug NYPOZI is now for sale in the US market through overseas marketing partner ...

Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for ...

The EMA’s recommendation marks a key step toward expanding treatment access for patients with psoriasis, psoriatic arthritis, ...

Under the agreement, Hikma will hold exclusive commercialisation rights in all MENA markets, while Celltrion will oversee ...

Ryan Haumschild, PharmD, MS, MBA:Dr [Kimberly] Chen, we talked about some of the challenges from the provider’s perspective. But I know there are challenges also from the payers’ perspective. What are ...

Alvotech ( ($ALVO) ) just unveiled an announcement. On October 6, 2025, Alvotech announced that the European Medicines Agency accepted a Marketing ...

Hungary’s largest drugmaker Gedeon Richter has received approval for its biosimilar products for the first time following a ...

With these new agreements, Hikma solidifies its position as a leading provider of biosimilars in the MENA region and takes a ...

India-based Biocon’s biosimilars subsidiary has reached a settlement and license agreement with Amgen that clears the path ...

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing ...